Sign in to view Pablo’s full profile
Welcome back
By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement, Privacy Policy, and Cookie Policy.
New to LinkedIn? Join now
or
By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement, Privacy Policy, and Cookie Policy.
New to LinkedIn? Join now
New York City Metropolitan Area
Contact Info
Sign in to view Pablo’s full profile
Welcome back
By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement, Privacy Policy, and Cookie Policy.
New to LinkedIn? Join now
or
By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement, Privacy Policy, and Cookie Policy.
New to LinkedIn? Join now
2K followers
500+ connections
Sign in to view Pablo’s full profile
Welcome back
By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement, Privacy Policy, and Cookie Policy.
New to LinkedIn? Join now
or
By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement, Privacy Policy, and Cookie Policy.
New to LinkedIn? Join now
View mutual connections with Pablo
Welcome back
By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement, Privacy Policy, and Cookie Policy.
New to LinkedIn? Join now
or
By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement, Privacy Policy, and Cookie Policy.
New to LinkedIn? Join now
View mutual connections with Pablo
Welcome back
By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement, Privacy Policy, and Cookie Policy.
New to LinkedIn? Join now
or
By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement, Privacy Policy, and Cookie Policy.
New to LinkedIn? Join now
Sign in to view Pablo’s full profile
Welcome back
By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement, Privacy Policy, and Cookie Policy.
New to LinkedIn? Join now
or
By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement, Privacy Policy, and Cookie Policy.
New to LinkedIn? Join now
Activity
Sign in to view Pablo’s full profile
Welcome back
By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement, Privacy Policy, and Cookie Policy.
New to LinkedIn? Join now
or
By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement, Privacy Policy, and Cookie Policy.
New to LinkedIn? Join now
-
startling nasa visualization of climate anomalies from 1880-2022
startling nasa visualization of climate anomalies from 1880-2022
Liked by Pablo Legorreta
Experience & Education
-
Royalty Pharma
******* & ***** ********* *******
-
****** ****** & **.
****-*********, ******* & ************
-
****** ****** ** ***
*********
-
*********** **************, ****** ** *é****
*.*. ** ********** ***********
-
View Pablo’s full experience
See their title, tenure and more.
Welcome back
By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement, Privacy Policy, and Cookie Policy.
New to LinkedIn? Join now
or
By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement, Privacy Policy, and Cookie Policy.
View Pablo’s full profile
Sign in
Stay updated on your professional world
By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement, Privacy Policy, and Cookie Policy.
New to LinkedIn? Join now
Other similar profiles
-
Jim Reddoch, PhD
New York, NYConnect -
Terrance Coyne
New York, NYConnect -
Sandy Balkin, Ph.D.
Scarsdale, NYConnect -
Marshall Urist
New York, NYConnect -
Matthew Lyons
New York, NYConnect -
Bruce Culleton
Greater BostonConnect -
Sam Landsberg
Senior Vice President, Finance and Treasurer at Royalty Pharma
New York, NYConnect -
Dean Kamen
Bedford, NHConnect -
Sara Klymkowsky
United StatesConnect -
Louise Richardson DBE
President at Carnegie Corporation of New York
New York, NYConnect -
Henri Fernandez
MBA Candidate at Stanford University Graduate School of Business
New York, NYConnect -
Aloe Blacc
Grammy-Nominated Artist 🎤 | Biotech Innovator 🧪 | Start-Up Angel 🚀 | Bridging Melodies with Molecules
Los Angeles, CAConnect -
Philip Liu
New York, NYConnect -
Rory Riggs
New York, NYConnect -
Gaurie Tilak
New York, NYConnect -
Vivian Liu, MD
New York, NYConnect -
Tim Bertram
Charlotte MetroConnect -
Ted W. Love, MD
Chair of the Board, Biotechnology Innovation Organization (BIO)
Burlingame, CAConnect -
Brian Pereira
Lexington, MAConnect -
Marc Engelsgjerd, MD
New York, NYConnect
Explore more posts
-
Pejman Nozad
Our partner Eddie Eltoukhy has identified these opportunities in Biotech. Eddie has a PhD in bioengineering from Massachusetts Institute of Technology and over a decade experience as an operator. Reach out to him if you are working on these areas of biotech. Pear VC - Technology-Driven Therapeutic Platforms Companies developing therapeutic assets with a core product engine Proprietary tool, workflow, or samples leading to novel biological data sets Preference for omics platforms or high throughput screening / engineering workflows First-in-class or best-in-class drugs - Next-Generation Therapeutic Modalities Technologies to improve the efficacy, safety, access, or reach of next-gen modalities including the following: Genomic medicines (gene tx & gene editing) Cell therapies Targeted protein degraders Antibody-drug conjugates Radiopharma - Precision Medicine New technologies supporting the discovery of novel biomarkers and the generation of proprietary data sets for applications in: Disease screening Therapy selection Recurrence monitoring - Life Sciences + AI Software Platforms Software & AI-driven platforms to improve all aspects of life sciences R&D, including: Target discovery and validation Drug design and optimization Manufacturing Regulatory Clinical development
120
5 Comments -
Vishnu Amble
Private markets fund managers and limited partners across the globe are no doubt enamored by the fundraising powers of Andreessen Horowitz as limited partners, particularly sovereign wealth funds, insurance companies and others with large minimums are lining up to make commitments and access the various strategies across the Andreessen Horowitz alternative asset supermarket which include #seed, #growth, #crypto, #gaming, #digital #bio, and now raising a private equity fund! I am not sure of the financial #returns of the strategies, but I am sure this private equity fund will be well-received by limited partners (especially #middleeast and #asiapacific) and that will continue the capital flows into the firm's other strategies and overall platform, which are often highly #oversubscribed and are able to charge premium management fees (ie higher than 2% annually) as well as tiered #carriedinterest ie 25% and above for higher than 2.0X/2.5X net performance. #fundraising #alternativeassets #privateequity #a16z #privatemarkets #venturecapital #capitalmarkets #sovereignwealthfunds #insurancecompanies #pensionfunds https://lnkd.in/g8ZaBHiY
46
1 Comment -
James Vena
NEW YORK, April 30, 2024 /PRNewswire/ -- PRISM Consulting Partners, a Florida based healthcare private practice acquisition advisory and consulting company, and Lion Management Services Organization of New York, have partnered to form PRISM Concierge. PRISM Consulting Partners was formed in 2023 by founders Michael Guelcher, David Molle, and Brian Whitman. The three partners have over 60 years combined experience in acquisitions, transitioning practices, and healthcare business development. Lion Management was founded in 2021 by James Vena, a Wall Street veteran with 35 years of value creation and capital investment experience. Lion Management implements and manages strategic solutions for private healthcare practices. The newly formed PRISM Concierge aims to be a full-service provider to private healthcare practitioners looking for options ranging from maximizing profit to ultimately transitioning to their desired outcome. The client receives management of back-office services tailored to achieve that outcome. "PRISM Concierge offers the mechanisms and resources to achieve a higher level of freedom," states Michael Guelcher, PRISM Partner. "Change readiness encompasses discipline now, for more freedom and greater rewards later." David Molle goes on to state, "We're filling a void in the healthcare market by bringing together shared resources and services that will ultimately improve a practice's bottom line, while freeing up time to allow for better patient care. Essentially, we're doing the things Drs. don't get paid to do. From shared billing and credentialling, to consultants, attorneys, IT, HR, and a complete group purchasing organization to name a few, your "concierge" can help with most aspects of your business as a single point of contact." James Vena, CEO, Lion Management is enthused about the impact PRISM Concierge can have in the marketplace. "Our recent success of organizing a group of 20 practices in a short window and making them the 35th largest eyecare practice in just two years translates well. We are embarking on something that has never been done before, and there is considerable demand for these services." About PRISM Consulting: https://lnkd.in/ed3gHdVd About Lion Management Services https://lnkd.in/ei-cpseE https://lnkd.in/ei-cpseE #eyecare #privateequity #healthcare #eyewear #optometrist #exits #mso #managementservices
10
4 Comments -
Lucy Stapleton
Strong preparation and restoring confidence will be key for the resurgence of M&A activity. We are already seeing signs that deal preparation is gearing up, and once confidence follows, we expect the market—and dealmakers—will move quickly. Learn about the current dealmaking imperatives and what dealmakers can do to prepare in our mid-year outlook: https://pwc.to/4enzPxD #PwCDeals #IndustryTrends #SaveTheDate
152
-
Michael Sidgmore
As private markets welcome more investors to the space, the how becomes as important as the why. iCapital Chairman & CEO Lawrence Calcano came on the Alt Goes Mainstream podcast to break down the how and the why. How can investors gain access to private markets in ways that work for them? How can alternative asset managers better serve those investors? How can this all be done in a responsible, thoughtful way that sets up both investors and private markets for success in the long-term? What is the evolution of the different service models that enable GPs to unlock access to private markets for more LPs? Lawrence Calcano and I discussed these topics and more on the show. Thanks Lawrence for coming on the show to share your thoughtful perspectives on the industry and its continued evolution. Thanks to Ultimus Fund Solutions for sponsoring this episode of the Alt Goes Mainstream podcast. https://lnkd.in/eX7njq8b
30
2 Comments -
David Young
We have issued the Cooley LLP Q1 2024 Venture Financing Report. Although deal activity and invested capital increased across all stages, down rounds also reached a new high (I guess down round is better than no round!). Separate from this, we continue to see an increase in deals at early phases across growth rounds, M&A and IPOs, which is encouraging. The video below provides a snapshot of the data and the full report is on CoolelyGo: https://bit.ly/44phRWQ
56
1 Comment -
Chad Fox
Family Offices & Venture Capital: The Shift From Direct Investments To Partner Funds This article hits the nail squarely on the head. Most family offices do not have the time, capacity or expertise to be top decile venture capital investors. Why is this important? Because top decile is the only place you make any money in venture. More family offices are realizing this and choosing to partner with top VC funds. F Partners Read The Full Article Here: https://lnkd.in/es3wapMy #singlefamilyoffice #familyoffices #familyoffice #privateinvestors #privatemarkets #vc
136
16 Comments -
Danielle Whitley
With the first quarter of 2024 now behind us, analysts are reviewing the #venturecapital dealmaking landscape for the year so far. Key highlights from the recently published CB Insights State of Venture Q1 2024 report reveal a mixed performance in VC dealmaking at the start of the year. #CBInsights #DealMaking
4
-
Damir Ibrahimagic Kopinic
🌟💰 Cendana & Kline Hill Launch $105M Fund for Secondary Stakes in Seed VC Funds💰🌟 📢Cendana Capital, a fund of funds that invests in dozens of seed-stage venture firms, and Kline Hill Partners, a firm focused on buying small previously owned private assets, are announcing a new $105 million Kline Hill Cendana Partners fund, which is well above the $75 million target, reported TechCrunch. 🔊“Over the past 2 years, we’ve been hearing from our portfolio funds, ‘We have a family office that wants to sell their $2 million commitment. Would you be interested in buying it?'” said Michael Kim, founder and managing director of Cendana Capital. "As we navigate the evolving VC landscape, this fund offers a unique opportunity to buy stakes in seed-stage VC funds and startups at relative bargains," shares Michael Kim. 💡💸 Led by Kim and Chris Bull, CFA of Kline Hill Partners, this joint venture combines expertise and relationships to navigate the secondary market with precision. "Our goal is to capitalize on the current buyer's market in venture capital," says Bull. 🌐🤝 "With traditional secondary investors eyeing the venture space, the competition is fierce. However, our focus on seed-stage firms sets us apart," explains Kim. 📈💼 Cendana’s relationships with its portfolio funds, including Lerer Hippeau, Forerunner Ventures and Bowery Capital, are helping it take the lead on sourcing secondary deals. Cash-hungry venture investors, whether VCs themselves or their LPs, are increasingly looking to sell their illiquid positions to secondary buyers. As they embark on this venture, the firms are poised to make a significant impact on the VC ecosystem, providing much-needed liquidity and unlocking new opportunities for growth. "The future looks bright for Cendana and Kline Hill's joint endeavor," concludes Bull. 🌟💰 With the demand for liquidity in the VC space at an all-time high, Cendana and Kline Hill's initiative couldn't come at a better time. By facilitating secondary transactions in seed-stage funds, they're not only providing relief to cash-hungry investors but also fueling innovation and growth in the startup ecosystem. 🌱💡 As the venture capital landscape continues to evolve, partnerships like these will play a crucial role in ensuring the health and sustainability of the industry. With their proven track record and strategic approach, Cendana and Kline Hill are well-positioned to lead the way forward. 🚀🌐 ✅ Looking to raise capital for your #fund and increase the international pool of your LP #investors? 🤝 Need warm #LP introductions? 📝 Selling #secondaries to increase liquidity? 🧐 Looking for co-investments? ▶ G+QUANT's link for inquiries and fund decks: https://lnkd.in/gjC_EuTE #VentureCapital #SecondaryMarket #SeedFunding #Innovation #StartupInvesting #Entrepreneurship #CendanaCapital #KlineHillPartners #VCInvestment #SeedStage #LiquidityOpportunity #FutureofVC #InnovativePartnerships
75
2 Comments -
Dennis Hinton
Unlike most private equity firms that are "operationally focused" - we take a different approach: Since we look to back A+ owner / operators, we typically do not get involved in day to day operational decisions. We prefer to be an asset to the business owner on high level strategic decisions including: financing decisions, tuck-in acquisitions, growth initiatives, when to sell 100%, etc.
65
2 Comments -
Eric Janson
Private Equity funds are elevating their operating teams and partners as a key driver of value creation at their underlying portfolio companies. Learn how to implement these changes for greater success. #PrivateEquity #PrivateCapital David Brown I Hugh Lloyd Ellis I Kevin Desai I Steve Roberts I Mairi McInnes
51
-
Arthur Andrew Bavelas
Today LIVE in 1 hour: Lead investor Andreessen Horowitz (a16z) Bio + Health team in Arda Therapeutics joins us today for Family Office Insights Mercury Series Webinar featuring Adam Freund of Arda Therapeutics. Today: June 10 2024, 02:15 PM Eastern Time : RSVP: https://lnkd.in/gNyhUPuh Cells are the functional units of life. They are also the functional units of disease: many chronic diseases are caused by certain cell populations becoming too abundant or active. For example, subsets of stromal cells drives fibrosis, while the hyperactivity of particular immune cells leads to chronic inflammation. Arda Therapeutics is developing medicines to precisely remove these pathogenic cells, thereby treating diseases more effectively than by blocking individual proteins or signaling pathways. Their proprietary, single-cell-based discovery engine identifies pathogenic cells and specific markers to target them. They then design therapies to eliminate these - and only these - cells.
1
-
Nicole Fourgoux
I love this! Thank you to Rachel Brown from Beauty Independent to kick-off this exchange with Andrew Ross' provocative thesis and have us all react to it. I truly enjoyed reading everyone's thoughts on the topic of the shortening lifecycle of beauty brands. Here is a snippet of mine: "Because beauty brand lifespans are shortening, it is important that we are able to differentiate brands with staying power from brands that will end up being a flash in the pan. There are much more of the latter than the former in the market right now, and if a brand is not well-positioned, it will be challenging for that brand to survive over the long-term. That’s why we focus on understanding each brand’s differentiators and long-term relevance." See more here: https://lnkd.in/esVbwnu2 and you will discover what Kevin Murphy, Odile Roujol, Rich Gersten, Tina Henry Bou-Saba, Oliver Nordlinger, Claire Chang, Manica Blain, Sonya Brown, George Birman had to say. #beautyindustry #beautyinvesting Stride Consumer Partners
11
4 Comments -
Max Dezara
Let's talk exit timing. Most private equity firms with a fund structure have time constraints on their hold period. For our team at Akoya, there's some real advantages since we don't have a typical fund structure (we're an independent sponsor). We don't have any predetermined timeframes with an exit, so we tend to look at things from a longer term perspective and can bring very patient capital to our investments. For us, we're looking for a path to a 3x return. That's how we're underwriting our investments. And so we'll do what's necessary to bolster the team so we can achieve at least three times the return on investment capital. That said, it's also important that we leave a lot of meat on the bones for the next firm. We don't want to extract every last dollar of value—we want to be sure that the next buyer has opportunity to achieve their own 3x return on investment. In short, for us, exit timing is not prescriptive. We don't go into it with a defined exit strategy. We'll look to sell at the optimal time. If you had a fund and your fund was going to end its life during COVID, you'd be kind of up a creek without a paddle, right? Thankfully, we don't have any of those constraints. #exitstrategy #investment #ROI #holdperiod
19
3 Comments -
Christy Carter
Excited to announce the first whitepaper in our permanent capital series; 'Tapping into Private Wealth and Retail Demand.' This publication provides a deep dive into how evolving capital sources play a role in offering flexible investment solutions. The paper provides: · A detailed examination of private wealth and retail demand for alternative assets. · Insights into the rising influence of Permanent Capital Vehicles (PCVs), which are revolutionizing access for private wealth and retail investors. · Key considerations for asset managers to adapt to these evolving market conditions. With large pockets of unmet demand for private assets in wealth channels, understanding semi-liquid PCVs is essential for asset managers. Access our in-depth analysis here: https://lnkd.in/epYPYG4r #permanentcapital #PrivateWealth #Retail
10
-
Natasha Kaye
Cooley LLP's Q1 2024 Venture Financing Report is live, showing that down rounds reached a new high and invested capital increased across all stages of financing. Watch the video for a snapshot at the data and head to Cooley GO for the full analysis, including spotlights on the technology and life sciences sectors, here: https://bit.ly/44phRWQ #CooleyGO #venturefinancings #venturecapital #report
1
Explore collaborative articles
We’re unlocking community knowledge in a new way. Experts add insights directly into each article, started with the help of AI.
Explore MoreOthers named Pablo Legorreta
-
Pablo Legorreta
Dallas-Fort Worth Metroplex -
Pablo Legorreta
Summer Financial Analyst at Locus Analytics
New York City Metropolitan Area -
Juan Pablo Legorreta Salazar
Account Manager en Google
Naucalpan de Juárez, MEX -
Pablo Gonzalo Escobar Legorreta
Partner at Escobar, Castillo & Monsiváis, S.C.
Mexico City, Mexico
16 others named Pablo Legorreta are on LinkedIn
See others named Pablo Legorreta